Drug Trial Radar · NCT04518501
Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer
Last checked: Nov 19, 2026Latest source record: Dec 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Jul 1, 2020
Primary completion
Dec 3, 2024
Study completion Jan 1, 2025
Sponsor
- Lead sponsor
- Xing XieAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 19, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Ovarian cancer is the leading cause of death from gynecologic tumors in the western world. Most patients have relapses, and responses to subsequent therapies are generally short-lived. Currently, the population that can benefit from PARPi is mainly focusing on BRCAm, then homologous-recombination deficiency patients. Limited data revealed the ORR was only 3-4% in homologous recombination proficiency patients with PARPi therapy. New treatments are urgently needed to improve patient outcomes. To explore the efficacy and safety of Fuzuloparib in combination with Arsenic trioxide therapy in platinum-resistance relapsed Ovarian cancer patients.
Conditions
- Efficacy and Safety
Interventions
Arsenic trioxide Tablet +Fuzuloparib CapsulesDrug
Arsenic trioxide Tablet : 0.27\*9 tid po consecutive 21 days with 1 week rest. Fuzuloparib Capsules: 150 mg bid po
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORRTime frame: From date of randomization until PD or death from any cause, assessed up to 36 months.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Women's Hospital School Of Medicine Zhejiang University
Zhejiang, Hangzhou, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.